https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / J Dtsch Dermatol Ges 2007 Mar;5(3):190-62007-03-01 00:00:002019-02-15 09:19:43Dendritic cell-based immunotherapy of malignant melanoma: success and limitations
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-42007-03-01 00:00:002019-02-15 09:24:09Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-672007-03-01 00:00:002019-02-15 09:22:10Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-27 / Biomed. Pharmacother. 2007 Jul;61(6):306-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-27 / Biomed. Pharmacother. 2007 Jul;61(6):306-142007-02-27 00:00:002019-02-15 08:32:36Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-21 / Hum. Immunol. 2007 May;68(5):334-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-21 / Hum. Immunol. 2007 May;68(5):334-412007-02-21 00:00:002019-02-15 09:11:48alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-20 / Eur J Surg Oncol 2007 Dec;33(10):1191-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-20 / Eur J Surg Oncol 2007 Dec;33(10):1191-82007-02-20 00:00:002019-02-15 08:38:08A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-09 / Cancer Res 2007 Feb;67(4):1842-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-09 / Cancer Res 2007 Feb;67(4):1842-522007-02-09 00:00:002023-03-07 13:12:37Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-992007-02-07 00:00:002023-03-07 13:13:36Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-01 / J. Surg. Res. 2007 May;139(2):164-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-01 / J. Surg. Res. 2007 May;139(2):164-92007-02-01 00:00:002019-02-15 08:38:12A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-01 / Int. J. Cancer 2007 Feb;120(3):585-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-01 / Int. J. Cancer 2007 Feb;120(3):585-932007-02-01 00:00:002019-02-15 08:38:13Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice
